MetLife Investment Management’s Syndax Pharmaceuticals SNDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $466K | Hold |
49,732
| – | – | ﹤0.01% | 1708 |
|
|
2025
Q1 | $611K | Sell |
49,732
-783
| -2% | -$9.62K | ﹤0.01% | 1614 |
|
|
2024
Q4 | $668K | Buy |
50,515
+2,961
| +6% | +$39.1K | ﹤0.01% | 1635 |
|
|
2024
Q3 | $915K | Hold |
47,554
| – | – | 0.01% | 1442 |
|
|
2024
Q2 | $976K | Buy |
47,554
+7,230
| +18% | +$148K | 0.01% | 1360 |
|
|
2024
Q1 | $960K | Buy |
40,324
+5,569
| +16% | +$133K | 0.01% | 1324 |
|
|
2023
Q4 | $751K | Hold |
34,755
| – | – | 0.01% | 1455 |
|
|
2023
Q3 | $505K | Hold |
34,755
| – | – | ﹤0.01% | 1630 |
|
|
2023
Q2 | $727K | Buy |
34,755
+3,126
| +10% | +$65.4K | 0.01% | 1449 |
|
|
2023
Q1 | $668K | Buy |
31,629
+3,702
| +13% | +$78.2K | ﹤0.01% | 1463 |
|
|
2022
Q4 | $711K | Buy |
27,927
+898
| +3% | +$22.9K | 0.01% | 1409 |
|
|
2022
Q3 | $650K | Hold |
27,029
| – | – | 0.01% | 1448 |
|
|
2022
Q2 | $520K | Hold |
27,029
| – | – | ﹤0.01% | 1634 |
|
|
2022
Q1 | $470K | Buy |
27,029
+9,976
| +58% | +$173K | ﹤0.01% | 1808 |
|
|
2021
Q4 | $373K | Hold |
17,053
| – | – | ﹤0.01% | 1659 |
|
|
2021
Q3 | $326K | Hold |
17,053
| – | – | ﹤0.01% | 1776 |
|
|
2021
Q2 | $293K | Buy |
17,053
+5,838
| +52% | +$100K | ﹤0.01% | 1906 |
|
|
2021
Q1 | $251K | Hold |
11,215
| – | – | ﹤0.01% | 1929 |
|
|
2020
Q4 | $249K | Hold |
11,215
| – | – | ﹤0.01% | 1855 |
|
|
2020
Q3 | $166K | Hold |
11,215
| – | – | ﹤0.01% | 1976 |
|
|
2020
Q2 | $166K | Hold |
11,215
| – | – | ﹤0.01% | 2005 |
|
|
2020
Q1 | $123K | Buy |
+11,215
| New | +$123K | ﹤0.01% | 1966 |
|